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Aim of database: The overall aim is to monitor the quality of childhood cancer care in 
Denmark; to register late effects of treatment; to analyze complications of permanent central 
venous catheters (CVCs); to study blood stream infections in children with cancer; and to study 
acute toxicity of high-dose methotrexate infusions in children with leukemia.
Study population: All children below 15 years of age at diagnosis living in Denmark diagnosed 
after January 1, 1985 according to the International Classification of Diseases 10, including 
diagnoses DC00–DD48.
Main variables: Cancer type, extent of disease, treatment, participation in international 
studies, recurrence of malignant disease, survival, yearly follow-up status, causes of death, 
and development of secondary malignancies. Type of CVC, causes for removal of the CVC, 
type of blood stream infection, pathogens isolated, antimicrobial sensitivity, and outcome of 
antimicrobial chemotherapy.
Descriptive data: Since 1985, 4,944 children below 15 years of age have been registered 
in the database. There has been no significant change in the incidence of childhood cancer in 
Denmark since 1985. The 5-year survival has increased significantly since 1985 and is now 
86%. The median number of days from diagnosis to initiation of therapy is 7 days and in 80% 
of the children less than 14 days. Clinical data of 95% of the patients are reported to open 
international studies.
Conclusion: The survival of Danish children with cancer since 2003 compares favorably with 
other international population-based studies. The annual reports support the collaboration within 
pediatric oncology in Denmark.
Keywords: childhood cancer, epidemiology, survival, complications
Aim of the database
The Danish Childhood Cancer Registry (DCCR) is a nationwide clinical quality 
database whose aim it is to report on the quality indicators outlined in Table 1 in all 
Danish children below 15 years of age at the time of cancer diagnosis. Overall survival 
and relapse-free survival are analyzed with respect to cancer type, extent of disease, 
treatment modalities, response to treatment, and recurrence of malignant disease. Since 
2014 DCCR also serves as the basis for a national quality study of the use of central 
venous catheters (CVCs) and of the occurrence of blood stream infections in children 
with cancer. The aim of this part of the register is to study complications related to the 
use of CVCs, especially central line associated blood stream infection and mechanical 
complications (eg, thrombosis, leakage, accidental removal). The database reports on 
the quality indicators listed in Table 1.
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Finally, registrations of acute toxicity of high-dose 
methotrexate in children with acute lymphoblastic leukemia 
and data regarding late effects after treatment of childhood 
cancer are linked to DCCR.
Study population
All children below 15 years of age at diagnosis living in 
Denmark with a diagnosis of a neoplasm according to the 
International Classification of Diseases 10 (ICD10), includ-
ing diagnoses DC00–DD48 are included in DCCR.
All tunneled CVCs and all blood stream infections 
from 2015 and onward are registered in children below 
15 years of age at diagnosis (with one of the relevant ICD10 
diagnoses). 
Since 2008, toxicity data related to high-dose methotrex-
ate infusions in all Danish children and adults with acute 
lymphoblastic leukemia, treated according to the Nordic 
NOPHO ALL 2008 protocol, have been registered.
The unique Danish personal identity number allows 
for unambiguous linkage between DCCR and the Danish 
National Patient Registry, the National Pathology Registry, 
and the Danish Cancer Registry (DCR). This linkage allows 
identification of missing data. Consequently, data regarding 
the annual cancer incidence rate in children below 15 years 
of age and their survival status are 100% complete. In total, 
98% of children with cancer are treated at one of the four 
regional childhood cancer centers in Denmark (The Univer-
sity Hospitals in Copenhagen, Aarhus, Odense, and Aalborg). 
Research nurses at the four centers are responsible for retriev-
ing relevant clinical data on all newly diagnosed patients, and 
for entering these data into the database after validation by 
a local pediatric oncologist. At the time of diagnosis written 
informed consent from the parents is obtained for registration 
of clinical data in DCCR.
Main variables
The main variables of DCCR are presented in Table 2.
All tumors have been classified according to the Birch 
and Marsden classification1 and the ICD10 classification; and 
we are in the process of reclassifying patients according to 
the International Childhood Cancer Classification 32 and the 
ICD-O classifications.
For solid tumors and lymphomas, the date of diagnosis 
is defined as the date of the first paraclinical investiga-
tion (X-ray, ultrasound, computed tomography/magnetic 
resonance scan) which indicated what later could be patho-
logically confirmed as a cancer. For leukemia, the date of 
diagnosis is the day of the bone marrow biopsy/aspiration. 
The therapy start date is recorded and allows calculation of 
the diagnostic delay. This is one of the five national quality 
parameters (see Table 1) by which the regional pediatric 
oncology centers are evaluated in Denmark.
In each childhood cancer case the applied international 
treatment protocol is documented within DCCR database. This 
gives us an opportunity to calculate doses of the individual 
Table 1 Quality indicators of childhood cancer in Denmark
Number of patients treated according to and reported to an 
international protocol
5-year relapse-free survival
5-year overall survival
Number of patients dying from complications due to treatment
Days from diagnosis to start of treatment
Number of patients developing a secondary cancer
Number of BSi-related deaths within 30 days after the diagnosis of BSi
Number of BSis in which the microorganisms are sensitive to the applied 
first-line antimicrobial chemotherapy
Number of BSis per 1,000 CVC-days
Number of premature removals of CVC caused by infectious 
complications
Abbreviations: BSi, blood stream infection; CVC, central venous catheter.
Table 2 Main variables in the Danish Childhood Cancer Registry 
(DCCR)
Cancer data
CPR
Tumor type
Extent of disease (localization of metastases)
Date of diagnosis
Date of start of therapy
Type of therapy (operation, chemotherapy, irradiation, observation)
Treatment protocol
Reporting of clinical data according to international protocol
Response to initial therapy
Date of cessation of therapy
Relapse (date, localization, treatment and outcome of relapse)
Yearly follow-up
Disease status:
 Alive in complete remission
 Alive with active disease
 Development of secondary malignancy
 Death: date and cause of death
Tunneled central venous catheters (t-CVCs)
Type of t-CVC
Date of insertion of t-CVC
Date of removal of t-CVC
Cause for removal of t-CVC
Bacteremia
Date of bacteremia
Focus for the bacteremia
Microbiological agents
Bacterial drug sensitivity
Antibiotic treatment, type, and length
Result of antibacterial therapy
Abbreviation: CPR, cardiopulmonary resuscitation.
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chemotherapeutic drugs the child has received, which may 
have implications for the risk of developing late effects of the 
treatment. All surgeries with the attempt of tumor removal are 
recorded, including the completeness of tumorectomy. For 
radiation therapy the total dose and the dates are registered, 
however data regarding the target or size of the field are not 
reported. The registered treatment data, which have been agreed 
upon by the regional pediatric oncology centers in Denmark, 
are .95% complete. Since it is a primary goal that all children 
should be treated according to the best international protocols 
and that clinical data should be reported where possible, it is 
also registered whether patient data have been reported to inter-
national studies. In total, 95% of Danish children with cancer 
are treated according to an international protocol. Data of 95% 
of those patients who are treated according to an open protocol 
are reported to ongoing international studies. This is another 
national quality indicator (see Table 1) by which the regional 
pediatric oncology centers in Denmark are evaluated.
Once a year the registrations in DCCR database are 
cross-checked with the Danish National Patient Registry to 
detect missing patients, and with the DCR in order to register 
secondary cancers which may have developed after the child 
has survived into adulthood. The lag time for identifying 
secondary cancers via the DCR is about 1 year. Furthermore, 
on a yearly basis all patients diagnosed after January 2003 are 
scrutinized for disease status including relapse and relapse 
therapy, deaths, and emigration (lost to follow-up) by medi-
cal record review and by cross-checking the Danish Civil 
Registration System.
Main results
Since 1985 4,944 children below 15 years of age have been 
registered in DCCR database. There has been no significant 
change in the incidence of childhood cancer in Denmark since 
1985. The annual incidence varies between 15.5 and 22.2 
cases per 100,000 children below 15 years of age (Figure 1). 
The recurrence-free 5-year survival for all cancers diagnosed 
between 2003 and 2014 was 74%, and the 5-year survival 
has increased significantly and steadily from 72% in19853 to 
86% in 2014. Three percent of all newly diagnosed children 
died from a treatment related cause, mostly children with 
leukemia and lymphoma. The median number of days from 
date of diagnosis to initiation of therapy was, in 2014, 7 days 
and in 80% of the children it was less than 14 days. Sixty-six 
secondary cancers have been registered in the population of 
4,800 children below 15 years of age diagnosed between 
1985 and 2014. Data regarding cancer types and survival are 
annually transferred electronically to the Nordic databases 
for leukemia, lymphoma, and solid tumors in Stockholm, 
Sweden.4 Relevant data are registered to Nordic and other 
international studies in 95% of children in which this registra-
tion is possible. The entire yearly report of DCCR is published 
on the homepage of the Danish Pediatric Hematology and 
Oncology (DAPHO) group. Data from DCCR have been 
outlined in the annual reports from 2008–2014.5
Data from DCCR were important in the PhD thesis by 
Ahrensberg, describing the diagnostic delay from the first 
symptom to start of treatment in children with cancer in 
Denmark diagnosed between 2008 and 2012.6–8
Also, data have been included in a Nordic study of 
the psycho-social effects of having had cancer during 
childhood.9–11
Funding and administration
DCCR is funded by the Danish Regions and the annual 
report is coordinated through the organizational umbrella, 
the Danish Clinical Registries (RKKP). The Danish Child-
hood Cancer Foundation provides funding for research 
nurses at the four centers responsible for data collection 
and registration.
A DCCR database steering group has been appointed 
with regional representatives from the pediatric oncology 
centers at the four university hospitals in Denmark, and from 
the Department of Clinical Epidemiology, Aarhus Univer-
sity Hospital. The chairman of this group, together with the 
Department of Clinical Epidemiology will write the annual 
report which will be discussed in the steering committee 
before publication.
Conclusion
The survival of Danish children with cancer since 2003 
compares favorably with other international population-based 
estimates.12,13 The annual reports are stimulating for the col-
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Figure 1 Yearly cancer incidence in children in Denmark 1985–2014.
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laboration within the DAPHO group. The reports focus on 
areas where there is room for improvement, for example, in 
connection with the reporting of clinical data according to 
international clinical trials. Data from DCCR have formed the 
basis for a series of Danish pediatric oncology PhD studies. 
An overall survival rate reaching 86% in childhood cancer 
treatment demonstrates a need to further improve the moni-
toring of patients for the development of late complications 
of cancer therapy, including secondary cancers. DCCR has 
been further developed to allow for recording of late effect 
parameters related to the treatment given.
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